2025 neurotech funding totals $4.8 billion across 140 deals — therapeutic neuromodulation dominates at $4B+
Summary
Naveen Rao's Neurotech Futures 2025 Funding Snapshot published in January/February 2026 found that the private neurotech market raised $4.8 billion across 140 deals in 2025 — a dramatic increase from prior years. Therapeutic or "treat/modify" neurotech (implanted and external neuromodulation head to toe, including all cranial implants and BCI) totaled more than $4 billion across approximately 100 deals. Analytic or "read/analyze" tech (AI, cognitive assessments, digital health, EEG applications) totaled $941 million across 41 deals. New categories gaining funding momentum in 2025 included oncology, women's health, chronic disease, and inflammation alongside the traditional BCI, SCS, and TMS markets.
Why it matters
The 2025 neurotech total of $4.8B across 140 deals is the largest single-year private investment in the history of neurotechnology — roughly 3x the 2022 total. The breakdown revealing therapeutic neuromod captures $4B+ (83%) while analytic/diagnostic captures $941M (20%) reflects where commercial revenue is most near-term accessible: therapeutic devices have established reimbursement codes while diagnostic analytics are still building their payer evidence base.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial